glp-1 agonists blindness risk The Role of Glucagon-Like Peptide-1 Receptor in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome People Going Blind From GLP-1:

As superoxide is subject to efficient dismutation by cellular superoxide dismutases, it is possible that NFT might directly interact with Keap1 to induce the observed release of Nrf2 and its escape from proteasomal degradation

By restoring optimal GH function, these peptides may reduce fine lines, improve skin tone, increase bone density, and enhance vitality , offering a non-synthetic anti-aging solution that supports healthy aging from within

Studies investigating muscle dysfunction in chronic fatigue syndrome have shown that patients exhibit an overreliance on this anaerobic metabolism even during low-level, everyday activities, leading to prolonged intramuscular acidosis and a slowed ability to clear protons from the tissue

Thats my only real comment

doi: 10.3390/molecules25010182